{
    "clinical_study": {
        "@rank": "146448", 
        "arm_group": {
            "arm_group_label": "Tamoxifen", 
            "arm_group_type": "Experimental", 
            "description": "Tamoxifen 20 mg daily for 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "Treat Barrett's esophagus (BE) patients with tamoxifen to Barrett's metaplasia as measured\n      by changes in Barrett's esophagus appearance by endoscopy and histology as well as changes\n      in SOX2 and CDX2."
        }, 
        "brief_title": "Tamoxifen to Treat Barrett's Metaplasia", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Barrett Metaplasia", 
        "condition_browse": {
            "mesh_term": [
                "Barrett Esophagus", 
                "Metaplasia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Treat Barrett's esophagus (BE) patients with tamoxifen to  determine the effects on\n      Barrett's metaplasia as measured by changes in Barrett's esophagus appearance by endoscopy\n      and histology.  Tamoxifen treatment may induce SOX2 expression, decrease CDX2 and promote\n      esophageal stem cell activity, leading to regression of Barrett's metaplasia. To test this\n      hypothesis, we will conduct a prospective, pilot study where patients with BE, without high\n      grade dysplasia, are treated with tamoxifen and assessed for changes in the appearance of\n      their BE by endoscopy and histology as well as changes in the SOX2/CDX2 ratio indicative of\n      an improvement in BE metaplasia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Biopsy-proven Barrett's esophagus that is non-dysplastic or with low grade dysplasia.\n\n          -  At least 18 years of age.\n\n          -  ECOG performance status \u2264 2\n\n          -  Normal bone marrow and organ function as defined below:\n\n               -  Absolute neutrophil count \u22651,500/mcl\n\n               -  Platelets \u2265 100,000/mcl\n\n               -  AST(SGOT)/ALT(SGPT) \u2264< 1.5 x IULN\n\n               -  Creatinine within normal institutional limits or creatinine clearance \u2265 60\n                  mL/min/1.73 m2 for patients with creatinine levels above institutional normal\n\n          -  Women of childbearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control, abstinence) prior to study entry and\n             for the duration of study participation.  Should a woman become pregnant or suspect\n             she is pregnant while participating in this study, she must inform her treating\n             physician immediately.\n\n          -  Ability to understand and willingness to sign an IRB approved written informed\n             consent document.\n\n        Exclusion Criteria:\n\n          -  Prior history of esophageal cancer.\n\n          -  Prior history or current use of tamoxifen or anti-estrogen therapy.\n\n          -  A history of allergic reactions attributed to compounds of similar chemical or\n             biologic composition to tamoxifen.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          -  Pregnant and/or breastfeeding. Female patients must have a negative urine pregnancy\n             test within 14 days of study entry.\n\n          -  Known HIV-positivity and on combination antiretroviral therapy because of the\n             potential for pharmacokinetic interactions with tamoxifen. Appropriate studies will\n             be undertaken in patients receiving combination antiretroviral therapy when\n             indicated.\n\n          -  Taking medications known to affect drug metabolism via the CYP3A4, CYP2C9, or CYP2D6\n             pathways.\n\n          -  History of blood clots (i.e. pulmonary embolism, DVTs).\n\n          -  Concurrent use of anticoagulants (i.e. Coumadin/warfarin)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089386", 
            "org_study_id": "201404013"
        }, 
        "intervention": {
            "arm_group_label": "Tamoxifen", 
            "description": "Tamoxifen 20 mg daily for 12 weeks", 
            "intervention_name": "Tamoxifen", 
            "intervention_type": "Drug", 
            "other_name": [
                "Nolvadex\u00ae", 
                "Soltamox\u00ae"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Tamoxifen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 30, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "alockhar@dom.wustl.edu", 
                "last_name": "A. Craig Lockhart, M.D.", 
                "phone": "314-362-5740"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Jean Wang, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jason Mills, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Tamoxifen to Treat Barrett's Metaplasia", 
        "overall_contact": {
            "email": "alockhar@dom.wustl.edu", 
            "last_name": "A. Craig Lockhart, M.D.", 
            "phone": "314-362-5740"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "A. Craig Lockhart, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The biopsy procedures with 4 quadrant biopsies/2 cm for histology and additional biopsies for freezing for macromolecular analysis to assess the preliminary diagnostic value of this marker pair in identifying levels of metaplasia in BE and as an indicator of response to tamoxifen treatment. The tissue from the two endoscopic procedures will be assessed for changes in the following related to tamoxifen therapy: 1) changes in the length of Barrett's esophagus involvement; and 2) the specific studies included to assess the response to tamoxifen.", 
            "measure": "Extent of Barrett's involvement and changes in histology", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "reference": [
            {
                "PMID": "16404367", 
                "citation": "Lindblad M, Garc\u00eda Rodr\u00edguez LA, Chandanos E, Lagergren J. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer. 2006 Jan 16;94(1):136-41."
            }, 
            {
                "PMID": "22001866", 
                "citation": "Huh WJ, Khurana SS, Geahlen JH, Kohli K, Waller RA, Mills JC. Tamoxifen induces rapid, reversible atrophy, and metaplasia in mouse stomach. Gastroenterology. 2012 Jan;142(1):21-24.e7. doi: 10.1053/j.gastro.2011.09.050. Epub 2011 Oct 14."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089386"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The main outcome measurements are SOX2 and CDX2, analyzed as a ratio. We will use a one sample paired non-parametric Wilcoxon test to test the significant difference if the ratio difference is not normally distributed. Normality assumption can be examined by visual Q-Q plot and formal Kolmogorov-Smirnov statistic. In addition, we will explore the patient level characteristics on treatment effect using a linear regression model. Specifically, we will use the difference ratio as the response variable and patient characteristics of interest as explanatory variables. Regression coefficients associated with the explanatory variables quantify the effect of these variables on the difference ratio, with t or F statistic testing for the statistical significance.", 
                "measure": "Changes in SOX2 and CDX2 expression", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "description": "Assess the tolerance of tamoxifen in this patient population as measured by CTCAE version 4.0", 
                "measure": "Tolerance of tamoxifen", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}